The total return over the past 12 months is -90.95% vs. +16.94% for the S&P 500. So far it's up -91.05% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (90.90%) | (84.94%) | (86.81%) | (65.12%) | (53.75%) | (47.16%) |
| Total Return CAGR | (90.95%) | (84.97%) | (86.83%) | (65.14%) | (53.77%) | (47.17%) |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Ernexa Therapeutics Inc. (ERNA)
| Year | Start price | End price | ERNA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $30.00 | $2.70 | (91.05%) | +14.51% | (105.56%) |
| 2025 | $110.25 | $30.00 | (72.79%) | +17.72% | (90.51%) |
| 2024 | $675.00 | $110.25 | (83.66%) | +24.89% | (108.55%) |
| 2023 | $1,207.50 | $675.00 | (44.10%) | +26.19% | (70.29%) |
| 2022 | $31,275.00 | $1,207.50 | (96.14%) | (18.17%) | (77.97%) |
| 2021 | $33,600.00 | $31,275.00 | (6.92%) | +28.74% | (35.66%) |
| 2020 | $33,000.00 | $33,600.00 | +1.82% | +18.37% | (16.55%) |
| 2019 | $29,250.00 | $33,000.00 | +12.82% | +31.22% | (18.40%) |
| 2018 | $63,150.00 | $29,250.00 | (53.68%) | (4.56%) | (49.12%) |
| 2017 | $127,500.00 | $63,150.00 | (50.47%) | +21.70% | (72.17%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
